Biopharma manufacturing company Repligen Corporation (NASDAQ: RGEN) will be reporting earnings this Tuesday before market hours. Here’s what to expect.
Repligen beat analysts’ revenue expectations last quarter, reporting revenues of $204.1 million, up 11.9% year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ organic revenue estimates.
Is Repligen a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Repligen’s revenue to grow 9.6% year on year, slowing from the 21.9% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Repligen rarely misses Wall Street’s revenue estimates.
Looking at Repligen’s peers in the life sciences tools & services segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Medpace delivered year-on-year revenue growth of 8.5%, meeting analysts’ expectations, and Thermo Fisher reported revenues up 9.1%, topping estimates by 1.4%. Medpace traded down 1.5% following the results while Thermo Fisher was also down 1.6%.
Read our full analysis of Medpace’s results here and Thermo Fisher’s results here.
There has been positive sentiment among investors in the life sciences tools & services segment, with share prices up 2.7% on average over the last month. Repligen is down 8.8% during the same time and is heading into earnings with an average analyst price target of $201.45 (compared to the current share price of $177.03).
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
